Wegovy (semaglutide) is an FDA-approved medicine for chronic weight management. CagriSema is Novo Nordisk's investigational fixed-dose combination of semaglutide and cagrilintide, an amylin analogue.
The most direct comparison evidence comes from REDEFINE 1. In that 68-week phase 3 trial, average weight loss was 20.4% with CagriSema and 14.9% with semaglutide 2.4 mg. The observed difference was 5.5 percentage points. It is a result from one trial, not a fixed amount that every patient can expect.
How the medicines differ
| Feature | Wegovy | CagriSema |
|---|---|---|
| Components | Semaglutide | Cagrilintide plus semaglutide |
| Receptor activity | GLP-1 | Amylin plus GLP-1 |
| Schedule studied | Once weekly injection | Once weekly injection |
| US status | FDA-approved | Investigational; application under FDA review |
Cagrilintide and semaglutide act through different receptor systems involved in appetite regulation. A second mechanism does not by itself establish better safety or outcomes. The trial results carry the comparison.
REDEFINE 1: direct comparison without diabetes
The peer-reviewed REDEFINE 1 report included 3,417 adults with obesity or overweight and at least one related condition, without diabetes. Participants received CagriSema, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo alongside lifestyle intervention.
At week 68, the treatment-policy analysis found:
| Group | Average body-weight change |
|---|---|
| CagriSema | -20.4% |
| Semaglutide 2.4 mg | -14.9% |
| Cagrilintide 2.4 mg | -11.5% |
| Placebo | -3.0% |
The 5.5-point CagriSema-versus-semaglutide gap was observed within this trial. It should not be converted into a guaranteed number of pounds for an individual.
Higher weight-loss thresholds
In the same treatment-policy analysis:
- 34.7% of CagriSema participants lost at least 25% of body weight, compared with 14.8% on semaglutide.
- 19.3% of CagriSema participants lost at least 30%, compared with 8.7% on semaglutide.
These responder rates replace an earlier rounded claim that about 37% reached 25% weight loss.
REDEFINE 2: participants with type 2 diabetes
The peer-reviewed REDEFINE 2 trial enrolled 1,206 adults with overweight or obesity and type 2 diabetes. Average weight loss at 68 weeks was 13.7% with CagriSema and 3.4% with placebo under the treatment-policy estimand.
REDEFINE 2 did not include a semaglutide-only comparator. Its results should not be used as a direct CagriSema-versus-Wegovy comparison.
Adverse events and discontinuation
Gastrointestinal effects were common in both phase 3 trials. The peer-reviewed reports provide the following all-cause adverse-event discontinuation rates:
| Trial | CagriSema | Placebo |
|---|---|---|
| REDEFINE 1 | 5.9% | 3.5% |
| REDEFINE 2 | 8.4% | 3.0% |
In REDEFINE 1, 3.6% of CagriSema participants permanently stopped treatment because of gastrointestinal events, compared with 1.3% on semaglutide and 0.6% on placebo. In REDEFINE 2, the corresponding rates were 4.8% and 0.7% for CagriSema and placebo.
The trials allowed dose delays or reductions. Trial tolerability may not match every person's experience in routine care.
FDA review and possible launch timing
CagriSema is not FDA-approved. Novo Nordisk submitted its US application in December 2025 and has said an FDA decision is anticipated by late 2026 in its official program update.
A US launch could begin around the start of 2027 if the FDA approves the application and the company is ready to supply it. That timing is conditional, not a confirmed on-sale date. No approved list price or insurance-coverage policy is available before approval.
What the evidence does not answer
REDEFINE 1 shows a direct average difference between CagriSema and semaglutide 2.4 mg, but it does not tell an individual which treatment will work better or be easier to tolerate. It also does not provide instructions for switching from Wegovy.
Anyone considering a medication change should review the approved label, medical history, response, side effects, and access with a prescriber. Until CagriSema is approved, Wegovy and other approved medicines remain the available options.
This article is for informational purposes only and does not constitute medical advice. Individual results vary.
Frequently asked questions
Did CagriSema cause more weight loss than Wegovy in REDEFINE 1?
In REDEFINE 1, average weight loss at 68 weeks was 20.4% with CagriSema and 14.9% with semaglutide 2.4 mg, the active ingredient and dose used in injectable Wegovy. The observed difference was 5.5 percentage points in that trial.
How many REDEFINE 1 participants lost at least 25% or 30%?
In the treatment-policy analysis, 34.7% of CagriSema participants lost at least 25% of body weight and 19.3% lost at least 30%.
Is CagriSema available?
CagriSema remains investigational while its FDA application is reviewed. A US launch could begin around the start of 2027, but only if approval is granted.
